Navigation Links
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
Date:10/25/2007

idated Statements of Operations (Unaudited)

The following represents condensed financial data (in thousands) except

per share data:

Three- Three- Nine- Nine-

Months Months Months Months

Ended Ended Ended Ended

September September September September

30, 2007 30, 2006 30, 2007 30, 2006

($) ($) ($) ($)

Net Sales 11,840 11,481 25,908 27,929

Gross profit 6,939 6,260 14,052 13,882

Sales & marketing expenses 1,077 1,283 4,637 4,796

Administrative expenses 2,683 3,195 9,366 10,001

Research & development 2,020 892 4,796 2,534

Income taxes (benefit) - - - 89

Net income (loss) 1,329 1,079 (4,119) (2,994)

Diluted loss per share:

Net income (loss) $0.10 $0.08 ($0.32) ($0.25)

Diluted weighted average

common shares outstanding: 13,143,276 13,242,127 12,693,300 12,163,858

Consolidated Balance Sheets (Unaudited)

The following represents condensed financial data (in thousands) at

September 30, 2007 and December 31, 2006:

2007 2006

($) ($)

Cash & cash equivalents 12,484 17,757

Accounts receivable, net 6,959 6,557

Inventory 5,803 4,262

Total curre
'/>"/>

SOURCE The Quigley Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)...  With the heroin epidemic in the ... Jacksonville -based Lakeview Health drug and alcohol treatment ... explain why fentanyl is causing a new wave of ... more potent than pharmaceutical grade heroin and often illegally ... of death skyrockets. "Fentanyl can be an ...
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been ... Place, N.Y. "I specialize in manual therapy, and my invention will provide headache ... used for additional muscle dysfunction throughout the body." , They developed THE RELIEVER ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is a ... field in the military. All too often VA hospitals treat patients with harmful and ... the VA program over a decade ago, the reality is that only 10% of ...
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... , WASHINGTON, Sept. 18 The ... every VA medical site with endoscopic equipment, independently verifying the ... and sterile procedures for reprocessing endoscopic equipment across the country. ... provide the highest quality care to the Veterans of this ...
... in hospital patients also leads to higher costs, study ... popular stomach acid reducer greatly increases the risk of ... study has found. , Researchers at Wake Forest University ... of 834 cardiothoracic surgery patients on breathing machines who ...
... , WASHINGTON, Sept. 18 In response to the ... Max Baucus, DMLR Chairman Stuart L. Weinstein, M.D. issued the following ... Baucus is inadequate in addressing the serious problems caused by medical ... health care policy experts, opinion leaders, and patients all across the ...
... , , , WEINER,S NEW YORK ... , WASHINGTON, Sept. 18 The Public Option is still ... ,fading, nor ,waning, (New York Times) nor on ,life support, (ABC News)," says ... Health subcommittee, and later spokesman for the White House National Drug Policy Office. ...
... , , IDAHO FALLS, Idaho, ... announces the successful conclusion of a private placement completed among ... International Isotopes Inc. successfully completed a private placement ... $1 million. In this private placement, the Company offered ...
... N.Y., Sept. 18 IPRO has won a new ... research findings aimed at improving the quality and safety ... Agency for Healthcare Research and Quality,s (AHRQ,s) Knowledge Transfer/Implementation ... accelerated dissemination of evidence-based products that improve the quality ...
Cached Medicine News:Health News:Inspector General Completes Study of VA Endoscopic Programs 2Health News:Ulcer Preventative May Raise Pneumonia Risks 2Health News:Statement From Stuart L. Weinstein, MD, Chairman, Doctors for Medical Liability Reform on Senator Baucus' Health Care Reform Proposal 2Health News:Public Option Still Viable As House Set to Pass It -- Not 'Fading,' Says Robert Weiner, Former House Aging Committee Director 2Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 2Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 3Health News:IPRO Wins Knowledge Transfer/Implementation Federal Contract From AHRQ 2
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
Medicine Products: